期刊文献+

突变型异柠檬酸盐脱氢酶1(IDH1)水平与人脑胶质瘤细胞增殖和血管增生正相关 被引量:3

The expression of IDH1( R132H) is positively correlated with cell proliferation and angiogenesis in glioma samples
下载PDF
导出
摘要 目的研究人胶质瘤中异柠檬酸盐脱氢酶1突变体(IDH1R132H)表达水平与肿瘤细胞增殖活性和血管形成之间的关系。方法采用测序法和免疫组织化学染色法检测IDH1突变情况和IDH1(R132H)表达水平,采用免疫组织化学染色法分析胶质瘤Ki-67标记指数,采用CD34免疫组织化学染色分析人胶质瘤组织中的血管数量,通过统计学方法,分析胶质瘤中IDH1(R132H)表达水平与肿瘤Ki-67标记指数和血管数量的相关性。结果 IDH1在Ⅱ级、Ⅲ级胶质瘤及继发性胶质母细胞瘤中突变率较高,且IDH1(R132H)表达水平与胶质瘤Ki-67和微血管密度存在明显的正相关。结论 IDH1在Ⅱ、Ⅲ级胶质瘤和继发胶质母细胞瘤中表达水平高,且突变型IDH1(R132H)的表达水平可能在胶质瘤的增殖和血管形成中发挥重要作用。 Objective To explore the correlations of the expression of mutant isocitrate dehydrogenase( IDH1)( R132H)protein with angiogenesis and cell proliferation in glioma. Methods We performed polymerase chain reaction-based IDH gene mutation screening in 385 glioma samples,and the subcellular localization and expression levels of IDH1( R132H) was examined by immunohistochemistry( IHC). Ki-67 labeling index was introduced to determine the proliferation of glioma cells,and the microvessel density was measured through CD34 staining. Statistical analyses were performed to show the correlations of IDH1 mutation with cell proliferation and microvessel density. Results The mutant rates of IDH1 were about 50%-60% in grade Ⅱ-Ⅲ gliomas and secondary glioblastomas,which were significantly higher than those in pilocytic astrocytoma( gradeⅠ)and primary glioblastoma( grade Ⅳ). Moreover,the level of IDH1( R132H) protein was positively correlated with Ki-67 labeling index and microvessel density. Conclusion IDH mutation was common in grade Ⅱ-Ⅲ glioma and secondary glioblastoma,and the mutant IDH1( R132H) might play a critical role in the cell proliferation and angiogenesis of glioma.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2016年第3期360-363,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金(81572471)
关键词 胶质瘤 IDH1 细胞增殖 血管增生 glioma IDH1 proliferation angiogenesis
  • 相关文献

参考文献25

  • 1Yan H, Parsons D W, Jin G, et al. IDH1 and IDH2 mutations in gliomas[ J]. N Engl J Med, 2009, 360(8): 765-773.
  • 2Kalinina J, Carroll A, Wang L, et al. Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma [ J]. J Mol Med(Berl), 2012, 90(10) : 1161 -1171.
  • 3Zhen H N, Zhang X, Hu P Z, et al. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas[J]. Cancer, 2005, 104(12): 2775-2783.
  • 4Metallo C M, Gameiro P A, Bell E L, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia [ J ]. Nature, 2012, 481 (7381) : 380 - 384.
  • 5Koh H J, Lee S M, Son B G, et al. Cytosolic NADP γ-dependent isocitrate dehydrogenase plays a key role in lipid metabolism [ J ]. J Biol Chem, 2004, 279(38) : 39968 -39974.
  • 6Parsons D W, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme [ J ]. Science, 2008, 321 (5897) : 1807 - 1812.
  • 7Zou P, Xu H, Chen P, et al. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliorms: a meta-analysis [ J/OL ]. PLoS One, 2013, 8: e68782, doi: 10. 1371/journal. pone. 0068782. Print 2013.
  • 8Zhu J, Zuo J, Xu Q, et al. Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients[ J]. Med Hypotheses, 2011, 76(4) : 602 -603.
  • 9Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype [ J]. Nature, 2012,483(7390): 479 -483.
  • 10杨燕武,谢飞,汤俊佳,刘双,王翔,刘艳辉,毛庆.IDH1基因突变对胶质瘤诊断及预后意义[J].中国现代神经疾病杂志,2012,12(6):712-718. 被引量:10

二级参考文献97

  • 1Louis D,Ohgaki H,Wiesler O,Cavenee W,eds. WHO classification of tumours of the central nervous system. 4th ed[ J. Lyon, France: IARC Press, 2007,114:97.
  • 2Yan H, Parsons Dw, Jin G, et al. IDH1 and IDH2 mutations in gliomas [ J ]. N Engl J Med,2009,360 : 765.
  • 3Parsons D, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme[ J]. Science,2008,321 : 1807.
  • 4Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors[ J]. Acta Neuropatho1,2008,116:597.
  • 5DeBerardinis R, Lum J, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation [ J 1. Cell Metab,2008,7 : 11.
  • 6Geisbrecht B, Gould S. The human PICD gene encodes a cytoplasmic and peroxisomal NADP ( + )-dependent isocitrate dehydrogenase [ J]. J Biol Chem, 1999,274 : 30527.
  • 7Gravendeel L, Kloosterhof N, Brahen L, et al. Segregation of non-p. R132H mutations in IDH1 in distinct molecular subtypes of glioma [ J ]. Hum Mutat,2010,31 : 1186.
  • 8Andreas von D, Andrey K, Christian H,et al. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations[J]. Brain Pathloaw.2010.74.
  • 9Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation[ J l. Acta Neuropathol Berlin, 2009,118:599.
  • 10Sonoda Y, Kumabe T, Nakamura T, et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients[ J]. Cancer Sci ,2009, 100 : 1996.

共引文献43

同被引文献16

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部